A. D. Beadell Investment Counsel Inc. Invests $876,000 in AstraZeneca PLC (NASDAQ:AZN)

A. D. Beadell Investment Counsel Inc. acquired a new stake in AstraZeneca PLC (NASDAQ:AZN) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 13,385 shares of the company’s stock, valued at approximately $876,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of AZN. Martin Investment Management LLC lifted its position in AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after purchasing an additional 7,615 shares during the last quarter. Integrated Advisors Network LLC increased its stake in AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after acquiring an additional 13,860 shares during the last quarter. Creative Planning lifted its stake in AstraZeneca by 8.0% during the third quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after purchasing an additional 16,692 shares during the last quarter. Soros Fund Management LLC increased its position in shares of AstraZeneca by 8.2% during the 3rd quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company’s stock valued at $206,677,000 after purchasing an additional 201,233 shares during the last quarter. Finally, Optas LLC raised its stake in shares of AstraZeneca by 173.5% during the third quarter. Optas LLC now owns 15,570 shares of the company’s stock worth $1,213,000 after acquiring an additional 9,877 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Up 0.9 %

Shares of AZN stock traded up $0.63 during mid-day trading on Friday, reaching $67.21. 2,141,876 shares of the company’s stock traded hands, compared to its average volume of 3,698,457. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The company’s 50-day moving average price is $66.20 and its 200-day moving average price is $75.01. The company has a market cap of $208.39 billion, a P/E ratio of 32.16, a P/E/G ratio of 1.19 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.87 EPS. On average, equities analysts expect that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.